Zacks Investment Research Upgrades Cynata Therapeutics (CYYNF) to Hold

Cynata Therapeutics (OTCMKTS:CYYNF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday, Zacks.com reports.

According to Zacks, “Cynata Therapeutics Ltd is a stem cell and regenerative medicine company. It is developing a therapeutic stem cell platform Cymerus(TM), a mesenchymal stem cell technology for human therapeutic use. Cynata Therapeutics Ltd is based in Armadale, Australia. “

Shares of CYYNF stock remained flat at $$0.81 during mid-day trading on Monday. The company’s stock had a trading volume of 500 shares, compared to its average volume of 75. Cynata Therapeutics has a twelve month low of $0.75 and a twelve month high of $1.12.



About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease.

Featured Article: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on Cynata Therapeutics (CYYNF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cynata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.